Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,920.00    -4.50 (-0.23%)
Bid:
1,919.50
Ask:
1,920.50
Spread: 1.00 (0.052%)
Market Cap: £76.95b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block listing Interim Review

15 Nov 2021 16:37

RNS Number : 4366S
GlaxoSmithKline PLC
15 November 2021
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 15 November 2021

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2021

To:

31 October 2021

Balance of unallotted securities under scheme(s) from previous return:

35,519

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

230,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

265,519

 

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2021

To:

31 October 2021

Balance of unallotted securities under scheme(s) from previous return:

382,466

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

3,000,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

313,319

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

3,069,147

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFZMMMVKKGMZM
Date   Source Headline
20th Mar 20257:00 amRNSTransaction in Own Shares
19th Mar 20257:00 amRNSTransaction in Own Shares
18th Mar 20257:00 amRNSTransaction in Own Shares
17th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20253:30 pmRNSDirector/PDMR Shareholding
14th Mar 20257:00 amRNSTransaction in Own Shares
13th Mar 20257:00 amRNSTransaction in Own Shares
12th Mar 20257:00 amRNSTransaction in Own Shares
11th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSTransaction in Own Shares
7th Mar 20257:00 amRNSTransaction in Own Shares
6th Mar 20257:00 amRNSTransaction in Own Shares
5th Mar 20257:00 amRNSTransaction in Own Shares
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20255:15 pmRNSGSK plc 2024 Annual Report on Form 20-F
3rd Mar 20253:00 pmRNSTotal Voting Rights
3rd Mar 20257:05 amRNSUS FDA accept 2 depemokimab indication submissions
3rd Mar 20257:00 amRNSANCHOR results presented at 2025 AAAAI
3rd Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 202510:00 amRNSGSK publishes Annual Report 2024
27th Feb 20257:00 amRNSTransaction in Own Shares
26th Feb 20254:00 pmRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSTransaction in Own Shares
25th Feb 20257:00 amRNSTransaction in Own Shares
24th Feb 20257:05 amRNSGSK completes acquisition of IDRx, Inc.
24th Feb 20257:00 amRNSGSK plc commences share buyback programme
21st Feb 20257:00 amRNSDirectorate Change
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
20th Feb 20257:00 amRNSNucala COPD submission accepted in China
17th Feb 20257:00 amRNSGSK 5-in-1 meningitis vaccine approved by US FDA
13th Feb 20253:30 pmRNSDirector/PDMR Shareholding
11th Feb 20253:30 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNSFinal Results
3rd Feb 20254:48 pmRNSTotal Voting Rights
28th Jan 20257:05 amRNSDepemokimab dual filing in China and Japan
28th Jan 20257:00 amRNSEMA accepts two submissions for depemokimab
27th Jan 20257:05 amRNSEMA accept review Shingrix syringe presentation
20th Jan 20257:00 amRNSJemperli expanded approval in the EU
16th Jan 20253:30 pmRNSDirector/PDMR Shareholding
15th Jan 20253:30 pmRNSDirector/PDMR Shareholding
14th Jan 20253:30 pmRNSDirector/PDMR Shareholding
13th Jan 20253:30 pmRNSDirector/PDMR Shareholding
13th Jan 20257:00 amRNSGSK enters agreement to acquire IDRx, Inc.
10th Jan 20257:00 amRNSShingrix fully liquid accepted for US FDA review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.